"Visit the UCLA Health website for coronavirus updates."

During the past decade, UCLA Hematology/Oncology Parkside conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 2 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCLA Hematology/Oncology Parkside" #1 sponsor was "Pfizer" with 4 trials, followed by "Dizal Pharmaceuticals" with 1 trials sponsored, "Eli Lilly and Company" with 1 trials sponsored, "G1 Therapeutics, Inc." with 1 trials sponsored and "Zymeworks Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA Hematology/Oncology Parkside" #1 collaborator was "Medivation, Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "UCLA Hematology/Oncology Parkside" are "Non-Small Cell Lung Cancer" (2 trials), "BRCA 1 Gene Mutation" (1 trials), "BRCA 2 Gene Mutation" (1 trials), "Breast Cancer Metastatic" (1 trials) and "Breast Neoplasm" (1 trials). Many other conditions were trialed in "UCLA Hematology/Oncology Parkside" in a lesser frequency.

Most popular intervention types in "UCLA Hematology/Oncology Parkside" are "Drug" (7 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Fulvestrant" (2 trials), "Abemaciclib" (1 trials), "Active Comparator (erlotinib)" (1 trials), "DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C" (1 trials) and "Dacomitinib (PF-00299804)" (1 trials). Other intervention names were less common.

The vast majority of trials in "UCLA Hematology/Oncology Parkside" are 8 trials for "All" genders.

Currently, there are NaN active trials in "UCLA Hematology/Oncology Parkside". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in UCLA Hematology/Oncology Parkside, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA Hematology/Oncology Parkside, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".